Jasper Therapeutics, a prominent clinical stage biotechnology company specializing in the development of briquilimab, has announced the appointment of Dr. Svetlana Lucas, Ph.D. to its esteemed Board of Directors. Dr. Lucas’ expertise in the field will undoubtedly contribute to the pioneering efforts of Jasper, particularly in addressing mast cell driven diseases like chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma. This significant development was made public on June 19th, 2024, solidifying Jasper’s commitment to revolutionizing antibody therapy.
Jasper Therapeutics has been at the forefront of groundbreaking research in the realm of biotechnology. With their primary focus on developing briquilimab, an innovative antibody therapy that specifically targets c-Kit (CD117), the company aims to combat various mast cell driven diseases. Chronic spontaneous urticaria, characterized by recurrent hives and itching, and chronic inducible urticaria, triggered by specific stimuli, pose significant challenges to patients’ quality of life. Additionally, asthma, a common respiratory condition, remains a constant struggle for millions worldwide. By pinpointing the root cause of these ailments, Jasper Therapeutics aims to introduce targeted and effective treatments.
The appointment of Dr. Svetlana Lucas, Ph.D. to the Board of Directors is an important and strategic move for Jasper Therapeutics. Dr. Lucas brings a wealth of knowledge and expertise in the field of biotechnology, further enriching the diverse skill set of the company’s leadership. With her extensive background in mast cell biology and antibody therapy, Dr. Lucas is poised to make significant contributions to Jasper’s mission. Her involvement will undoubtedly enhance the development of briquilimab and its potential to transform the treatment landscape for mast cell driven diseases.
Simultaneously, Jasper Therapeutics bids farewell to Anna French, D. Phil. who has stepped down from the Board, effective June 18, 2024. French’s contributions to the company are recognized and appreciated, and her departure paves the way for new opportunities and fresh perspectives with Dr. Lucas’ appointment.
With the inclusion of Dr. Lucas to the Board of Directors, Jasper Therapeutics solidifies its commitment to groundbreaking research and advancements in biotechnology. The wealth of knowledge and expertise brought by the esteemed Dr. Lucas perfectly aligns with the company’s vision to provide targeted treatments for individuals suffering from mast cell driven diseases. As the journey continues, Jasper Therapeutics takes a significant step forward in revolutionizing antibody therapy and providing hope for patients worldwide.
Comments